Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.280-92, 2011. ,
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.270-279, 2011. ,
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup, Alzheimers Dement, vol.7, issue.3, pp.263-272, 2011. ,
Safety and acceptability of the research lumbar puncture, Alzheimer Dis Assoc Disord, vol.19, issue.4, pp.220-225, 2005. ,
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry, World J Biol Psychiatry, vol.2017, pp.1-85 ,
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease, Biomark Med, vol.6, issue.4, pp.455-76, 2012. ,
Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?, Expert Rev Proteomics, vol.8, issue.4, pp.447-58, 2011. ,
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease, Alzheimers Dement, vol.4, pp.38-48, 2008. ,
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-262, 2006. ,
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, vol.302, pp.385-93, 2009. ,
Mild cognitive impairment as a diagnostic entity, J Intern Med, vol.256, issue.3, pp.183-94, 2004. ,
Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease, J Neurol Sci, vol.158, issue.2, pp.134-174, 1998. ,
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau, Neurobiol Aging, vol.25, issue.3, pp.273-81, 2004. ,
Decreased sA?PP?, A?38, and A?40 cerebrospinal fluid levels in frontotemporal dementia, J Alzheimers Dis, vol.26, issue.3, pp.553-63, 2011. ,
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load, J Neurochem, vol.101, issue.4, pp.1053-1062, 2007. ,
Cerebrospinal fluid A?1-40 improves differential dementia diagnosis in patients with intermediate P-tau 181P levels, J Alzheimers Dis, vol.36, issue.4, pp.759-67, 2013. ,
Evaluation of the cerebrospinal fluid amyloid-?1-42/amyloid-?1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders, Dement Geriatr Cogn Disord, vol.36, issue.1-2, pp.99-110, 2013. ,
Cerebrospinal fluid A?40 is similarly reduced in patients with frontotemporal lobar degeneration and Alzheimer's disease, J Neurol Sci, vol.358, issue.1-2, pp.308-324, 2015. ,
Cerebrospinal fluid amyloid-? 42/ 40 ratio in clinical setting of memory centers: a multicentric study, Alzheimers Res Ther, vol.7, issue.1, p.30, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01842465
Additional use of A? 42 /A? 40 ratio with cerebrospinal fluid biomarkers P-tau and A? 42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice, J Alzheimers Dis, vol.41, issue.2, pp.377-86, 2014. ,
Amyloid-? 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays, J Alzheimers Dis, vol.43, issue.1, pp.183-91, 2015. ,
The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia, Curr Alzheimer Res, vol.7, issue.5, pp.470-476, 2010. ,
Diagnostic accuracy of cerebrospinal fluid amyloid-? isoforms for early and differential dementia diagnosis, J Alzheimers Dis, vol.45, issue.3, pp.813-835, 2015. ,
CSF A?42/A?40 and A?42/A?38 ratios: better diagnostic markers of Alzheimer disease, Ann Clin Transl Neurol, vol.3, issue.3, pp.154-65, 2016. ,
Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau, A?42, and A?40) in prodromal stage of Alzheimer's disease and dementia with Lewy bodies, J Alzheimers Dis, vol.51, issue.4, pp.1069-83, 2016. ,
Relevance of A?42/40 ratio for detection of Alzheimer disease pathology in clinical routine: the PLMR scale, Front Aging Neurosci, vol.10, p.138, 2018. ,
Addition of the A?42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment, Alz Res Ther, vol.10, p.33, 2018. ,
Cerebrospinal fluid A?40 improves the interpretation of A?42 concentration for diagnosing Alzheimer's disease, Front Neurol, vol.6, p.247, 2015. ,
Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. Neural Transm (Vienna), vol.116, pp.1163-1170, 2009. ,
Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer's disease in pre-dementia subjects, J Alzheimers Dis, vol.48, issue.2, p.887, 2015. ,
Prediction of Alzheimer's disease using the CSF Abeta42/ Abeta40 ratio in patients with mild cognitive impairment, Dement Geriatr Cogn Disord, vol.23, issue.5, pp.316-336, 2007. ,
Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years, J Alzheimers Dis, vol.21, issue.4, pp.1119-1147, 2010. ,
Performance of A?1-40, A?1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment, J Alzheimers Dis, vol.29, issue.1, pp.229-267, 2012. ,
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia, Alzheimers Res Ther, vol.9, issue.1, p.84, 2017. ,
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings, Neurology, vol.78, pp.1568-75, 2012. ,
Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology, Arch Neurol, vol.68, pp.1398-403, 2011. ,
Do we still need positron emission tomography for early Alzheimer's disease diagnosis?, Brain, vol.139, issue.11, p.60, 2016. ,
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol, vol.6, pp.131-175, 2010. ,
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, Brain, vol.129, pp.3035-3076, 2006. ,
Low frequency of post-lumbar puncture headache in demented patients, Acta Neurol Scand, vol.88, pp.221-224, 1993. ,
Cerebrospinal fluid A?42/40 corresponds better than A?42 to amyloid PET in Alzheimer's disease, J Alzheimers Dis, vol.55, issue.2, pp.813-835, 2017. ,
Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease, Brain, vol.138, issue.3, pp.772-83, 2015. ,
Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography, Brain, vol.126, pp.1226-1262, 2016. ,
Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment, JAMA Neurol, vol.74, issue.12, pp.1492-501, 2017. ,
Pittsburgh compound B imaging and cerebrospinal fluid amyloid-? in a multicentre European memory clinic study, Brain, vol.139, issue.9, pp.2540-53, 2016. ,
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging, Alzheimers Dement, 2018. ,
Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies, J Alzheimers Dis, vol.42, issue.4, pp.421-430, 2014. ,
Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid, Cerebrospinal Fluid Res, vol.7, p.10, 2010. ,
Cerebral white matter lesionsassociations with A? isoforms and amyloid PET, Sci Rep, vol.6, p.20709, 2016. ,
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease, Ann Clin Biochem, vol.46, pp.235-275, 2009. ,
Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes, J Alzheimers Dis, vol.31, pp.13-20, 2012. ,
Chasing the effects of pre-analytical confounders -a multicenter study on CSF-AD biomarkers, Front Neurol, vol.6, p.153, 2015. ,
Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid, Clin Chem, vol.61, pp.734-777, 2015. ,
Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability, Clin Chim Acta, vol.449, pp.9-15, 2015. ,
Confounding factors influencing amyloid beta concentration in cerebrospinal fluid, Int J Alzheimers Dis, 2010. ,
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update, Biomark Med, vol.6, pp.419-449, 2012. ,
CSF biomarker variability in the Alzheimer's Association QC program work group, Alzheimers Dement, vol.9, pp.251-61, 2013. ,
Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides, Clin Chem, vol.52, issue.2, pp.332-336, 2006. ,
Cerebrospinal fluid A? 42 /A? 40 as a means to limiting tube-and storagedependent pre-analytical variability in clinical setting, J Alzheimers Dis, vol.57, issue.2, pp.437-482, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02450425
How to handle adsorption of cerebrospinal fluid amyloid ? (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A?42/A?40 ratio, Alzheimers Dement, vol.13, issue.8, pp.885-92, 2017. ,
Optimized standard operating procedures for the analysis of cerebrospinal fluid A?42 and the ratios of A? isoforms using low protein binding tubes, J Alzheimers Dis, vol.53, issue.3, pp.1121-1153, 2016. ,